Research programme: mRNA therapeutics - Alexion/Moderna Therapeutics

Drug Profile

Research programme: mRNA therapeutics - Alexion/Moderna Therapeutics

Alternative Names: ALXN 1540; ALXN 1630

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexion Pharmaceuticals; Moderna Therapeutics
  • Class RNA
  • Mechanism of Action Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hyperbilirubinaemia

Most Recent Events

  • 27 Jul 2017 Alexion terminates its license agreement with Arbutus Biopharma for the latter's lipid nanoparticle (LNP) technology
  • 27 Jul 2017 Alexion terminates its R&D agreement with Moderna Therapeutics for the development of mRNA Therapeutics
  • 27 Jul 2017 Discontinued - Preclinical for Hyperbilirubinaemia in USA (Parenteral) as a result of Alexion's redefined R&D strategy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top